Skip to main content

Table 2 IC50 of CB533, Pyr-1 and chemotherapeutic agents (Control) obtained from a panel of cancer cells

From: Discovery and cellular stress pathway analysis of 1,4-naphthoquinone derivatives with novel, highly potent broad-spectrum anticancer activity

Tissue Pyr-1, IC50 (nM) CB533, IC50 (nM) Control, IC50 (nM)
Breast
 BT4740 2.1 5.7 Dox: > 105
 MCF-7 2.8 72.8 Cis: 14,800
 SK-BR-3 1 5.4 Cis: 99,410
Colon
 CoLo205 3.2 42.9 Mit: 2610
 DLD-1 10.1 227 Cis: 4680
 HCT116 1.6 163.5 Mit: 4290
 HT29 4.7 170.3 Cis: 10,570
 SW480 1.4 88.4 Cis: ≈105
 SW620 0.9 55.3 Cis: > 105
Prostate
 LNCaP 18 1540 Cis: 13,520
 DU145 19 405.8 Cis: 1680
 PC-3 5.9 76.8 Cis: 18,270
Pancreas
 BxPC-3 4.5 108.8 Cis: 5550
 PANC-1 1.2 267 Cis: 4300
 MIA PaCa-2 16.9 283.9 Cis: 13,540
Lung
 A549 9.9 36.9 Cis: 11,740
 CaLu-6 14.4 242.3 Cis: 2380
 NCI-H460 6.9 714.6 Cis: 780
 NCI-H1703 19.5 nt Cis: 13,670
 SK-MES-1 12.8 382.5 Cis: 14,480
Myeloma
 RPMI-8226 12.6 59 Cis: 11,010
Ovary
 SK-OV-3 60.1 666.6 Mit: 1060
 OVCAR-3 0.6 46.8 Cis: 6310
Liver
 Hep 3B 76.2 197 Cis: 6950
 Hep G2 3.5 46.5 Mit: 2700
 SK-HEP-1 48 1454 Mit: 3500
Stomach
 BGC-823 10.5 172.5 Cis: 1250
 MCG803 3.3 179.3 Cis: 6550
 NCI-N87 2.2 310.3 Cis: 5830
Head and Neck
 KB 11.2 120.4 Cis: 12,340
 CNE2 8.4 971.6 Cis: 11,820
Kidney
 786-O 39.5 986.4 Cis: 4280
Sarcoma
 HT-1080 12.9 663.3 Dox: 320
 143B 19.1 1360 Mit: 1480
Melanoma
 A375 14.3 334.5 Cis: 7100
 SK-MEL-5 13.3 245.5 Cis: 5130
 A2058 1.7 511.5 Cis: 7240
Glioma
 U-87 MG 40 2144 Cis: 4480
Leukemia
 K-562 7.4 99.6 Cis: 2700
  1. Dox doxorubicin, Mit mitomycin C, Cis Cisplatin